This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Baxter Appoints Two New Directors To Its Board

Baxter International Inc. (NYSE:BAX) today announced it has appointed two new members to its Board of Directors, Uma Chowdhry, PhD, and Thomas F. Chen. The appointments are effective November 2012.

Chowdhry most recently served as Senior Vice President and Chief Science and Technology Officer at E.I. du Pont de Nemours before retiring in 2010. She started her career at DuPont in 1977 as a research scientist and held positions of increasing responsibility. Chowdhry holds a bachelor’s of science degree in physics and math from Mumbai University, a master’s degree in engineering science from California Institute of Technology and a PhD in materials science from Massachusetts Institute of Technology.

Chen most recently served as Senior Vice President, International Nutrition, at Abbott before retiring in 2010. During his Abbott career, he served in a number of roles of increasing responsibility, primarily in Pacific/Asia/Africa where he oversaw expansion into a number of emerging markets. Chen started his career with American Cyanamid in 1979 and earned a bachelor’s degree in international business from National Cheng Chi University in Taipei, and a master’s in business administration from Indiana University.

''The appointments of Uma and Thomas deepen the strength of the Baxter Board of Directors and align with our history of scientific and product innovation, and our international presence as a company,'' said Robert L. Parkinson, Jr., Baxter’s Chairman and Chief Executive Officer.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,704.76 -53.15 -0.30%
S&P 500 2,072.91 -4.51 -0.22%
NASDAQ 4,998.2550 -14.8680 -0.30%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs